Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) EBIT: TND Mil (TTM As of . 20)


XTUN:SIPHA Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
12 GF Score
Price TND4.01
! 1 Warning Sign
View Full Analysis

What is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T EBIT?

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA 12 EBIT is TND Mil as of . 20. GuruFocus rates XTUN:SIPHA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's earnings before interest and taxes (EBIT) for the six months ended in . 20 was TND0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T  (XTUN:SIPHA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T EBIT Related Terms

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T EBIT Historical Data

* Premium members only.

The historical data trend for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T EBIT Chart

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Annual Data
Trend
EBIT

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Semi-Annual Data
EBIT

XTUN:SIPHA vs BIEI, PTXTQ, INQD: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EV-to-EBIT falls into.


XTUN:SIPHA
12GF Score
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was TND Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of TND Mil mean?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a EBIT of TND Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EBIT too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current EBIT is TND Mil. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EBIT compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's EBIT of TND Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current EBIT is TND Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current EBIT of TND Mil. The current EBIT is TND Mil. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current EBIT is TND Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Business Description

Address Fondouk Choucha, Ben Arous, TUN, 2013
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score

Get the complete analysis for XTUN:SIPHA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

TND4.01
Price